<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03731130</url>
  </required_header>
  <id_info>
    <org_study_id>V1 10.07.2018</org_study_id>
    <nct_id>NCT03731130</nct_id>
  </id_info>
  <brief_title>Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant Radiation or Chemoradiation Followed by Surgery in Patients With Rectal Cancer</brief_title>
  <acronym>NEOCARE</acronym>
  <official_title>Radiation or Chemoradiation Followed by Surgery in Patients With Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational study to evaluate longitudinal quality of life according to standardized EORTC
      questionaires as well as functional Outcome, oncological outcome and toxicity in patients
      treated with neoadjuvant short term radiation or long-term chemoradiation followed by surgery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational study to evaluate longitudinal quality of life in patients treated with
      neoadjuvant short-course Irradiation or neoadjuvant Long-Course chemoradiation followed by
      surgery. QoL will be evaluated by standardized EORTC questionaires QLQ C30 and CR29. Acute
      and late toxicity will be assessed according to CTCAE 4.03. Oncological Outcome will be
      assessed with regard to local and distant Control, Patterns of recurrence, freedom from
      Treatment failure and Overall survival. Correlations of physicians- and Patient-assessed
      functional outcomes are planned.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>QoL (EORTC QLQC30) absolute values and change over time</measure>
    <time_frame>short-term radiation: day 0, end of week 1, 14, 27, 53, 105, 157, 209, 261, long-term chemoradiation: day 0, end of week 6, 14, 27, 40, 66, 118, 170, 222, 274</time_frame>
    <description>Quality of life measured by EORTC questionaires QLQC30 in absolute values at different time points and change over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QoL (EORTC QLQCR29) absolute values and change over time</measure>
    <time_frame>short-term radiation: day 0, end of week 1, week 14, 27, 53, 105, 157, 209, 261, long-term chemoradiation: day 0, end of week 6, 14, 27, 40, 66, 118, 170, 222, 274</time_frame>
    <description>Quality of life measured by EORTC questionaires QLQCR29 in absolute values at different time points and change over time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>acute toxicity</measure>
    <time_frame>short-term radiation: day 0, end of week 1, long-term chemoradiation: day 0, end of week 6, 14</time_frame>
    <description>acute toxicity by Radiation or chemoradiation according to CTCAE 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late toxicity</measure>
    <time_frame>short-term radiation: end of week 27, 53, 105, 157, 209, 261, long-term chemoradiation: end of week 27, 40, 66, 118, 170, 222, 274</time_frame>
    <description>late toxicity according to CTCAE 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local control</measure>
    <time_frame>short-term radiation: day 0, end of week 1, 14, 27, 53, 105, 157, 209, 261, long-term chemoradiation: day 0, end of week 6, 14, 27, 40, 66, 118, 170, 222, 274</time_frame>
    <description>Absence of local regrowth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant control</measure>
    <time_frame>short-term radiation: day 0, end of week 1, 14, 27, 53, 105, 157, 209, 261, long-term chemoradiation: day 0, end of week 6, 14, 27, 40, 66, 118, 170, 222, 274</time_frame>
    <description>Absence of distant metastases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>freedom from Treatment failure</measure>
    <time_frame>short-term radiation: day 0, end of week 1, 14, 27, 53, 105, 157, 209, 261, long-term chemoradiation: day 0, end of week 6, 14, 27, 40, 66, 118, 170, 222, 274</time_frame>
    <description>Absence of local or distant relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>short-term radiation: day 0, end of week 1, 14, 27, 53, 105, 157, 209, 261, long-term chemoradiation: day 0, end of week 6, 14, 27, 40, 66, 118, 170, 222, 274</time_frame>
    <description>Absence of death from any cause</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Rectal Cancer</condition>
  <condition>Quality of Life</condition>
  <condition>Radiation Therapy</condition>
  <condition>Chemoradiation</condition>
  <arm_group>
    <arm_group_label>neoadjuvant short term radiation</arm_group_label>
    <description>Treatment with neoadjuvant short term radiation therapy (5x5 Gy) followed by surgery. Quality of life will be assessed using the EORTC QLQ C30 and EORTC QLQ CR 29 questionaire.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>neoadjuvant long-term chemoradiation</arm_group_label>
    <description>Treatment with neoadjuvant Long-term chemoradiation followed by surgery. Quality of life will be assessed using the EORTC QLQ C30 and EORTC QLQ CR 29 questionaire</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EORTC QLQ C30</intervention_name>
    <description>standardized questionaire</description>
    <arm_group_label>neoadjuvant long-term chemoradiation</arm_group_label>
    <arm_group_label>neoadjuvant short term radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EORTC QLQ CR29</intervention_name>
    <description>standardized questionaire</description>
    <arm_group_label>neoadjuvant long-term chemoradiation</arm_group_label>
    <arm_group_label>neoadjuvant short term radiation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        see eligibility criteria
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically proven rectal Cancer without distant metastases

          -  indication for neoadjuvant Radiation or chemoradiation therapy according to
             multidiciplinary Evaluation

          -  age &gt;=18 years

          -  written informed consent

          -  ability to answer the standardized questionaires according to the treating physician

        Exclusion Criteria:

          -  age &lt; 18 years

          -  prior systemic therapy with regard to rectal Cancer

          -  distant metastasis

          -  second malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Falk Roeder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ludwig-Maximilians Universität München</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Falk Roeder, MD</last_name>
    <phone>+49 89 4400</phone>
    <phone_ext>73729</phone_ext>
    <email>Falk.Roeder@t-online.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sabine Gerum, MD</last_name>
    <phone>+49 89 4400</phone>
    <phone_ext>73770</phone_ext>
    <email>Sabine.Gerum@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Radiation Oncology, University Hospital, LMU Munich</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Falk Roeder, MD</last_name>
      <phone>+49 89 4400 73729</phone>
      <email>Falk.Roeder@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Sabine Gerum, MD</last_name>
      <phone>+49 89 4400 73729</phone>
      <email>Sabine.Gerum@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Franziska Walter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Hoffmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 17, 2018</study_first_submitted>
  <study_first_submitted_qc>November 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2018</study_first_posted>
  <last_update_submitted>November 2, 2018</last_update_submitted>
  <last_update_submitted_qc>November 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Falk Roeder</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>quality of life</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>radiation therapy</keyword>
  <keyword>chemoradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

